Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1377-1387

  Sakano, Shigeru ^a   Hinoda, Yuji ^a   Sasaki, Miwa ^a   Wada, Takashi ^a   Matsumoto, Hiroaki ^a   Eguchi, Satoshi ^a   Shinohara, Asano ^a   Kawai, Yoshihisa ^a   Hara, Tomohiko ^a   Nagao, Kazuhiro ^a   Hara, Takahiko ^a   Naito, Katsusuke ^a,b   Matsuyama, Hideyasu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Urology   (Japan)

Author keywords

Adverse effects; bladder neoplasms; cisplatin; DNA repair; radiotherapy; SNP

Indexed keywords

CISPLATIN; GLYCINE; LYSINE; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RAMOSETRON; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XERODERMA PIGMENTOSUM GROUP G PROTEIN; XRCC1 PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DNA REPAIR; DOSE RESPONSE; EXCISION REPAIR; FEMALE; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PREDICTION; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DNA REPAIR; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PLATINUM; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 78149286935     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.106     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Rodel C, Grabenbauer GG, Kuhn R et al.: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol. 20(14), 3061-3071 (2002).
3. Dunst J, Rodel C, Zietman A, Schrott KM, Sauer R, Shipley WU: Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy Semin. Surg. Oncol. 20(1), 24-32 (2001).
4. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM: Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97(Suppl. 8), 2115-2119 (2003).
5. Suk R, Gurubhagavatula S, Park S et al.: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in nonsmall cell lung cancer patients. Clin. Cancer Res. 11(4), 1534-1538 (2005).
6. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61(24), 8654-8658 (2001).
7. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD: Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22(6), 917-922 (2001).
8. Khanna KK, Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27(3), 247-254 (2001).
9. Shinohara A, Sakano S, Hinoda Y et al.: Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci. 100(12), 2376-2382 (2009).
10. Matullo G, Peluso M, Polidoro S et al.: Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol. Biomarkers Prev. 12(7), 674-677 (2003).
11. Vodicka P, Kumar R, Stetina R et al.: Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25(5), 757-763 (2004).
12. Zhu Y, Yang H, Chen Q et al.: Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst.) 7(2), 141-148 (2008).
13. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell Biol. 19(2), 1092-1100 (1999).
14. Bond GL, Hu W, Bond EE et al.: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5), 591-602 (2004).
15. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11(12), 1513-1530 (2002).
16. Stern MC, Lin J, Figueroa JD et al.: Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: fndings from the international consortium of bladder cancer. Cancer Res. 69(17), 6857-6864 (2009).
17. Gurubhagavatula S, Liu G, Park S et al.: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22(13), 2594-2601 (2004).
18. Yoon SM, Hong YC, Park HJ et al.: The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63(3), 885-891 (2005).
19. Sakano S, Wada T, Matsumoto H et al.: Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br. J. Cancer 95(5), 561-570 (2006).
20. Gordon MA, Gil J, Lu B et al.: Genomic profling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7(1), 67-88 (2006).
21. Sanyal S, Festa F, Sakano S et al.: Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25(5), 729-734 (2004).
22. Sakano S, Kumar R, Larsson P et al.: A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. BJU Int. 97(4), 847-851 (2006).
23. Sakano S, Matsumoto H, Yamamoto Y et al.: Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. Pathobiology 73 (6), 295-303 (2006).
24. Sakano S, Hinoda Y, Okayama N et al.: The association of DNA repair gene polymorphisms with the development and progression of renal cell carcinoma. Ann. Oncol. 18(11), 1817-1827 (2007).
25. Sasaki M, Sakano S, Okayama N et al.: DNA repair gene polymorphisms may be associated with prognosis of upper urinary tract transitional cell carcinoma. Neoplasia 10(3), 255-265 (2008).
26. Shipley WU, Prout GR Jr, Einstein AB et al.: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258(7), 931-935 (1987).
27. Matsumoto H, Matsuyama H, Fukunaga K, Yoshihiro S, Wada T, Naito K: Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br. J. Cancer 91(6), 1025-1031 (2004).
28. Sakano S, Berggren P, Kumar R et al.: Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int. J. Cancer 104(1), 98-103 (2003).
29. Seaman SR, Muller-Myhsok B: Rapid simulation of P values for product methods and multiple-testing adjustment in association studies. Am. J. Hum. Genet. 76(3), 399-408 (2005).
30. Booton R, Ward T, Heighway J et al.: Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106(11), 2421-2427 (2006).
31. Wang Z, Xu B, Lin D et al.: XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 62(1), 99-104 (2008).
32. Chang-Claude J, Popanda O, Tan XL et al.: Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin. Cancer Res. 11(13), 4802-4809 (2005).
33. De Ruyck K, Van Eijkeren M, Claes K et al.: Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int. J. Radiat. Oncol. Biol. Phys. 62(4), 1140-1149 (2005).
34. Sakiyama T, Kohno T, Mimaki S et al.: Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int. J. Cancer 114(5), 730-737 (2005).
35. von der Maase H, Hansen SW, Roberts JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
36. Tsuchiya N, Inoue T, Narita S et al.: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J. Urol. 180(6), 2389-2395 (2008).
37. Lee CT, Madii R, Daignault S et al.: Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specifc and overall survival. J. Urol. 175(4), 1262-1267 (2006).
38. Kuricova M, Naccarati A, Kumar R et al.: DNA repair and cyclin D1 polymorphisms and styrene-induced genotoxicity and immunotoxicity. Toxicol. Appl. Pharmacol. 207(Suppl. 2), 302-309 (2005).
39. Chen M, Kamat AM, Huang M et al.: High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28(10), 2160-2165 (2007). (Pubitemid 47543377)
40. Vodicka P, Stetina R, Polakova V et al.: Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 28(3), 657-664 (2007).